Theravance Biopharma (TBPH) EPS (Weighted Average and Diluted): 2019-2025
Historic EPS (Weighted Average and Diluted) for Theravance Biopharma (TBPH) over the last 6 years, with Sep 2025 value amounting to $0.07.
- Theravance Biopharma's EPS (Weighted Average and Diluted) rose 126.92% to $0.07 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.57, marking a year-over-year increase of 156.44%. This contributed to the annual value of -$1.15 for FY2024, which is 15.00% down from last year.
- Per Theravance Biopharma's latest filing, its EPS (Weighted Average and Diluted) stood at $0.07 for Q3 2025, which was down 93.52% from $1.08 recorded in Q2 2025.
- In the past 5 years, Theravance Biopharma's EPS (Weighted Average and Diluted) registered a high of $12.14 during Q3 2022, and its lowest value of -$1.35 during Q1 2021.
- In the last 3 years, Theravance Biopharma's EPS (Weighted Average and Diluted) had a median value of -$0.26 in 2024 and averaged -$0.11.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first surged by 1,697.37% in 2022, then plummeted by 101.40% in 2023.
- Over the past 5 years, Theravance Biopharma's EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.78 in 2021, then skyrocketed by 73.08% to -$0.21 in 2022, then rose by 19.05% to -$0.17 in 2023, then tumbled by 82.35% to -$0.31 in 2024, then soared by 126.92% to $0.07 in 2025.
- Its last three reported values are $0.07 in Q3 2025, $1.08 for Q2 2025, and -$0.27 during Q1 2025.